Sulforaphane Prevents Right Ventricular Injury and Reduces Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.

Sulforaphane Prevents Right Ventricular Injury and Reduces Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. Am J Physiol Heart Circ Physiol. 2020 Feb 28;: Authors: Kang Y, Zhang G, Huang EC, Huang J, Cai J, Cai L, Wang S, Keller BB Abstract Right ventricular (RV) dysfunction is the main determinant of mortality in patients with pulmonary arterial hypertension (PAH) and while inflammation is pathogenic in PAH there is limited information on the role of RV inflammation in PAH. Sulforaphane (SFN), a potent Nrf2 activator, has significant anti-inflammatory effects and facilitates cardiac protection in preclinical diabetic models. Therefore, we hypothesized SFN might play a comparable role in reducing RV and pulmonary inflammation and injury in a murine PAH model. We induced PAH using SU5416 and 10% hypoxia (SuHx) for 4 weeks in male mice randomized to SFN at a daily dose of 0.5 mg/kg, 5 days per week for 4 weeks or to vehicle control. Transthoracic echocardiography was performed to characterize chamber specific ventricular function during PAH induction. At 4 weeks we measured RV pressure and relevant measures of histology, protein, and gene expression.SuHx induced progressive RV, but not LV, diastolic and systolic dysfunction and RV and pulmonary remodeling, fibrosis, and inflammation. SFN prevented SuHx-induced RV dysfunction and remodeling, reduced RV inflammation and fibrosis, upregulated Nrf2 expression and its downs...
Source: American Journal of Physiology. Heart and Circulatory Physiology - Category: Physiology Authors: Tags: Am J Physiol Heart Circ Physiol Source Type: research